In conclusion, our findings support a model in which atorvastatin and rosuvastatin, under LPS-driven inflammatory priming in colorectal cancer cells, are associated with selective downregulation of protease-activated receptor 2 with sparing of protease-activated receptor 1, accompanied by attenuation of ERK pathway output and reduced tumour necrosis factor alpha production, together with multi node engagement of apoptotic signalling and Annexin V confirmed cell death. Here, MAPK1 is linked to colorectal cancer.